Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change

Previous studies have grouped all donors positive for hepatitis C virus (HCV) antibody (Ab). Only recently has donor HCV nucleic acid testing (NAT) become routine, and the impact of Ab and NAT status on organ utilization is unknown. Using the United Network for Organ Sharing database, we identified 9290 donors from 2015 to 2016 for whom both HCV Ab and NAT data were available and compared organ utilization by HCV status. Overall, 93.8% of donors were Ab negative and NAT negative (Ab−NAT−), 0.15% were Ab negative and NAT positive, 1.8% were Ab positive and NAT negative (Ab+NAT−), and 4.2% were both Ab and NAT positive (Ab+NAT+). Ab−NAT− donors donated at the highest rate for all organs except livers, of which Ab+NAT− donors donated at a higher rate (81.2% vs 73.2%, p = 0.03). Livers were discarded for reasons related to abnormal biopsies in Ab+NAT+ donors, whereas kidneys from Ab- or NAT-positive donors were discarded for reasons related to HCV status. Using a propensity score−matched model, we estimated that using Ab+NAT− donors at the same rate as Ab−NAT− donors could result in 48 more kidney donors, 37 more heart donors, and 15 more lung donors annually. We urge the use of HCV Ab+NAT− donors for appropriately selected and consenting recipients.